Obesity
Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
Published in Healthcare Finance, Tax and Law Weekly, May 21st, 2008
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the treatment of obesity. The objective of this dose-ranging study is to support dose selection for Phase 3, and to inform the ongoing development of a convenient delivery system for this combination regimen. The six-month, randomized, double-blind, placebo-controlled multi-center study will enroll approximately 600 overweight and obese subjects and is expected to complete in mid-2009.
"There is a tremendous medical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- AARP
AARP Welcomes Class of 2014 to its Board of Directors - AARP
Bill Novelli to Remain CEO of AARP - AARP
Third National GrandRally Brings Hundreds of Grandparents Raising Grandchildren to Washington - Abbott
Abbott to Present at Citi Investment Research Global Health Care Conference - Accor
Accor Sells Sofitel the Grand Amsterdam Under a Sale and Management-Back Agreement for EUR 92 Million - Adam Friedman Associates
Adam Friedman Associates, in Partnership with Friedland Events Announces Chinese Companies to Present at Spring 2008 China Growth Conference to Be Held May 22nd at the Harvard Club of New York City - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
